<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28178" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Radiation Esophagitis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nesheiwat</surname>
            <given-names>Zeid</given-names>
          </name>
          <aff>The University of Toledo</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Akbar</surname>
            <given-names>Hina</given-names>
          </name>
          <aff>University of Tennessee Health Sciences Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kahloon</surname>
            <given-names>Arslan</given-names>
          </name>
          <aff>University of Tennessee, Chattanooga</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mahajan</surname>
            <given-names>Kunal</given-names>
          </name>
          <aff>Holy Heart Advanced Cardiac Care Centre</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Zeid Nesheiwat declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hina Akbar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Arslan Kahloon declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kunal Mahajan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>23</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28178.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Radiation esophagitis is inflammation of the esophagus due to radiation. Radiation esophagitis is typically an adverse effect that develops in individuals receiving radiation cancer therapy, most commonly for breast, lung, and other lymphomas. Symptoms present two to three weeks after the initial therapy and include throat pain, dysphagia, and the sensation that food is stuck. Amifostine is a medication used as a radiation protector in selected populations at risk of radiation esophagitis. This activity describes the pathophysiology and presentation of radiation esophagitis and highlights the role of the interprofessional team in its management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the pathophysiology of radiation esophagitis.</p></list-item><list-item><p>Review the evaluation of a patient with radiation esophagitis.</p></list-item><list-item><p>Summarize the treatment options for radiation esophagitis.</p></list-item><list-item><p>Explain the importance of improving care coordination among interprofessional team members to improve outcomes for patients affected by radiation esophagitis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28178&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28178">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-28178.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Radiation esophagitis is inflammation of the esophagus due to radiation. Radiation esophagitis is typically an adverse effect that develops in individuals receiving radiation cancer therapy, most commonly for breast, lung, and other lymphomas. Symptoms present two to three weeks after the initial therapy and include throat pain, dysphagia, and the sensation that food is stuck. Amifostine is a medication used as a radiation protector in selected populations at risk of radiation esophagitis. Typically administered via injection 30 minutes before therapy, patient studies have been promising, showing a reduced risk of developing radiation esophagitis. The goal when treating this condition is adequate nutrition intake, and it is advisable for patients to refrain from eating hot or spicy foods that can further irritate the esophageal lining. In severe cases, perforations, ulcerations, dysmotility, and tracheoesophageal fistulas can be seen. Although there is no cure for radiation esophagitis, symptoms regress 2 to 4 weeks after the completion of radiation treatment.<xref ref-type="bibr" rid="article-28178.r1">[1]</xref><xref ref-type="bibr" rid="article-28178.r2">[2]</xref><xref ref-type="bibr" rid="article-28178.r3">[3]</xref></p>
      </sec>
      <sec id="article-28178.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Radiation esophagitis is inflammation, edema, erythema, and erosion of the mucosal surface of the esophagus caused by radiation therapy to nearby or related structures that cause cell damage, produce proinflammatory cytokines and lead to the&#x000a0;development of free-oxygen radical species related to radiation therapy.</p>
      </sec>
      <sec id="article-28178.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Radiation esophagitis is an adverse effect for patients undergoing radiation cancer therapy, usually for lung, breast, and other thoracic cancers due to its proximity. Symptomatic radiation esophagitis, however, is a rare complication of radiation therapy affecting the minority of patients undergoing treatment. In addition, genetics have been thought to play an important role in a patient who develops radiation esophagitis, with some research correlating single-nucleotide polymorphisms of transforming growth factor b-1 with severe radiation esophagitis.<xref ref-type="bibr" rid="article-28178.r4">[4]</xref><xref ref-type="bibr" rid="article-28178.r5">[5]</xref></p>
        <p>Certain risk factors may predispose patients to a high risk of developing radiation esophagitis. These include&#x000a0;White&#x000a0;race, age greater than 70, female sex, poor initial performance status, low body mass index, gastroesophageal reflux disease, and dysphagia.</p>
      </sec>
      <sec id="article-28178.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Radiation therapy leads to mucosal damage, production of pro-inflammatory cytokines, and eventually cell death which leads to ulcerations of the esophageal mucosal lining. Radiation therapy causes cell DNA damage, leading to stress-related, pro-inflammatory cytokine production through various signaling pathways and ultimately causing mucosal damage and irritation. If severe, ulcerations of the mucosal wall can occur.</p>
      </sec>
      <sec id="article-28178.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Endoscopy in the acute setting may reveal erythema, erosion, mucosal soughing, ulcerations, and hemorrhage. In the chronic setting, fibrosis, atypia, and chronic inflammatory changes may be seen.</p>
        <p>Effects of radiation esophagitis&#x000a0;predominately involve the basal cells of the squamous epithelium. Within 48 hours of radiation therapy, apoptotic bodies are seen. Within a few weeks, the submucosal layers of the esophagus become involved with mucosal gland degeneration, endothelial swelling, and capillary dilation creating erythema. Within one month, cytological atypia is described as having irregular nuclear membranes and abnormal smudge nuclei with loss of detail with prominent nuclei. In addition, the cytoplasm will reveal a bubble appearance, pleomorphism, cytomegaly, and hyperchromic nuclei with other common findings including parakeratosis and mucosal atrophy.</p>
        <p>In chronic esophagitis, fibroblasts and inflammatory cells infiltrate the muscle wall, leading to edema, and thickening of the submucosa, leading to fibrosis and stricture formation.</p>
      </sec>
      <sec id="article-28178.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients that develop radiation esophagitis&#x000a0;may have a history of&#x000a0;poor initial performance status, low body mass index, gastroesophageal reflux disease, and dysphagia. In addition, patients with esophageal infiltrated tumors or late-stage cancer have an increased risk of radiation esophagitis.</p>
        <p>When examining a patient with a history of cancer with radiation therapy, it is always important to ask about symptoms of the recurrent disease, i.e., weight loss, worsening respiratory status, dysphagia, or hoarseness. Clinicians should evaluate the oral mucosa extensively, looking for signs of thrush or lesions, evaluate for lymphadenopathy, and perform a thorough respiratory exam.</p>
        <p>Common symptoms include dysphagia, nausea, anorexia, and odynophagia.</p>
      </sec>
      <sec id="article-28178.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Radiation esophagitis can be classified as acute or late. Acute radiation esophagitis develops less than 3 months after therapy whereas late occurrences develop greater than 3 months after therapy. However, most cases of acute radiation esophagitis develop within 2 to 3 weeks post initial treatment and 6 months for late development. Symptoms may be cumulative but are typically self-limiting. In severe cases, dysmotility, perforations, fistula, and strictures can develop.<xref ref-type="bibr" rid="article-28178.r6">[6]</xref><xref ref-type="bibr" rid="article-28178.r7">[7]</xref></p>
        <p>The diagnosis is typically made clinically in these patients; however, if there is a concern for more serious complications, further diagnostics may be needed. A barium swallow should be used to&#x000a0;evaluate for esophageal strictures or impaired peristaltic waves and dysmotility. Chest and abdomen computed tomography (CT) may be used to evaluate for fistula and characterization of strictures. Upper endoscopy may be used to&#x000a0;evaluate&#x000a0;for ulcerations and biopsy if needed.</p>
      </sec>
      <sec id="article-28178.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment is supportive care with adequate hydration and nutrition intake. Amifostine, an organic triphosphate, has been studied and shown to act as a radioprotector. It is thought that this medication acts as an antioxidant to neutralize the free-oxygen radicals produced during ionizing radiation. A study performed&#x000a0;to look at the effects of amifostine in patients with advanced non-small-cell lung cancer showed improvement of swallowing dysfunction but no effect on reducing rates of esophagitis in severe cases. Another potential radioprotectant, glutamine, has been associated with reduced rates of esophagitis. A small prospective study in non-small cell lung cancer patients showed 49% reported no esophagitis when treated prophylactically with glutamine powder. Nonsteroidal anti-inflammatory drugs (NSAIDs) and other&#x000a0;drugs have been studied but have not proven effective.<xref ref-type="bibr" rid="article-28178.r8">[8]</xref><xref ref-type="bibr" rid="article-28178.r9">[9]</xref><xref ref-type="bibr" rid="article-28178.r10">[10]</xref></p>
        <p>Dietary modification in the form of soft, bland diets is typically used along with the removal of irritant foods such as alcohol, spicy foods, and very hot or cold foods. Frequent, small meals also help. Nutritional support may be needed, using supplements, intravenous hydration, electrolyte correction, and total parenteral nutrition. Analgesia is typically needed, using topical or systemic methods. Prophylactic antifungal therapy is indicated due to the increased risk of thrush.<xref ref-type="bibr" rid="article-28178.r11">[11]</xref><xref ref-type="bibr" rid="article-28178.r12">[12]</xref></p>
        <p>If a stricture is present, then dilatation may be required. However, complications like aspiration&#x000a0;and perforation are also potential problems.</p>
        <p>There are reports of the use of stents to relieve long strictures.</p>
      </sec>
      <sec id="article-28178.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Radiation esophagitis may develop in the acute stage of therapy or the chronic stage of therapy. Patients with severe esophagitis are at a higher risk of developing long-term complications, and clinicians must be able to recognize severe life-threatening complications such as ulcerations, perforations, fistula, and strictures. Additionally, cytomegalovirus (CMV) esophagitis must be ruled out in these patients.</p>
      </sec>
      <sec id="article-28178.s11" sec-type="Staging">
        <title>Staging</title>
        <p>
<bold>Grading of Radiation Esophagitis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>0 - No symptoms</p>
          </list-item>
          <list-item>
            <p>1 - Mild fibrosis and difficulty with swallowing solids</p>
          </list-item>
          <list-item>
            <p>2 - Dysphagia-dilatation may be required</p>
          </list-item>
          <list-item>
            <p>3 - Severe fibrosis, only able to swallow liquids, dilatation is necessary</p>
          </list-item>
          <list-item>
            <p>4 - Necrosis, perforation, or fistula formation</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28178.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Radiation esophagitis symptoms may be cumulative but they are typically self-limiting. There is no cure, but symptoms typically regress 2 to 4 weeks after the completion of radiation treatment.</p>
      </sec>
      <sec id="article-28178.s13" sec-type="Complications">
        <title>Complications</title>
        <p>Although radiation esophagitis is relatively benign and self-limiting, in severe cases, it can cause ulcerations, esophageal perforations, tracheoesophageal fistula, stricture development. Severe cases have been associated with genetic factors and polymorphisms.</p>
      </sec>
      <sec id="article-28178.s14" sec-type="Postoperative and Rehabilitation Care">
        <title>Postoperative and Rehabilitation Care</title>
        <list list-type="bullet">
          <list-item>
            <p>Spicy and very hot/cold foods should be avoided</p>
          </list-item>
          <list-item>
            <p>A soft pureed bland diet is preferred</p>
          </list-item>
          <list-item>
            <p>A dietitian consult can help assess the daily calorie requirement.</p>
          </list-item>
          <list-item>
            <p>Some patients may require IV hydration or tube feedings.</p>
          </list-item>
          <list-item>
            <p>The discomfort may respond to oral lidocaine, NSAIDs, and proton pump inhibitors (PPIs).</p>
          </list-item>
          <list-item>
            <p>Nystatin swish and swallow is highly recommended as these patients are also prone to thrush and candida esophagitis.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28178.s15" sec-type="Consultations">
        <title>Consultations</title>
        <p>In the absence of severe disease, i.e., perforation, ulceration, fistula, stricture, or severe malnutrition due to dysphagia, no consultations are needed. In cases where a procedure or endoscopic dilation is needed, a gastroenterologist or general surgeon consultation is appropriate.</p>
      </sec>
      <sec id="article-28178.s16" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Many agents have been studies to prevent radiation-induced&#x000a0;esophagitis. Amifostine, L glutamine, and NSAIDS have all been investigated with conflicting data. The key to prevention is awareness and obtaining a nutritional consult early in the disease.</p>
      </sec>
      <sec id="article-28178.s17" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>Current research has been looking at the use of granulocyte-macrophage colony-stimulating factor and honey to prevent radiation esophagitis.</p>
      </sec>
      <sec id="article-28178.s18" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Radiation esophagitis is a common problem in patients who receive upper-body radiation. The patient is often unable to eat solids and/or liquids. In addition, eating and swallowing are often associated with pain. The management of this condition is best accomplished with an interprofessional team approach. The nurse plays a vital role in educating the patient prior to radiation about this complication. Further, the nurse is responsible for monitoring the amount of food intake and weight gain/loss. The pharmacist can help lower the pain and the discomfort by providing viscous lidocaine and proton pump inhibitors/sucralfate. Because the patients are also prone to fungal esophagitis, the pharmacist must be proactive and encourage starting the patient on nystatin. Finally, the dietitian is vital as many patients may have difficulty eating. The dietitian can assess the calorie requirements and suggest alternative ways of delivering the calories. [Level 3]<xref ref-type="bibr" rid="article-28178.r13">[13]</xref></p>
        <p>
<bold>Outcomes</bold>
</p>
        <p>Despite advances in delivering radiation, esophagitis still continues to occur and carries high morbidity. The actual outcomes of patients with radiation esophagitis are not accurately reported but the numbers are not minuscule.</p>
        <p>However, the prognosis of radiation esophagitis is good. This disease process is an adverse effect of radiation therapy, and symptoms usually resolve within&#x000a0;2 to 4&#x000a0;weeks after radiation therapy has been completed. In some cases, with high dosage radiation, long-term complications include stricture formation or perforation. Emami et al. estimated that 5% of patients who received radiation therapy at 60 Gy developed late complications.</p>
        <p>Patients who underwent radiation and developed radiation esophagitis have a 5- to 10-fold increased risk of developing esophageal squamous cell carcinoma. Adequate long-term follow-up is needed. [Level 3]<xref ref-type="bibr" rid="article-28178.r14">[14]</xref></p>
      </sec>
      <sec id="article-28178.s19">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28178&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28178">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/radiation-esophagitis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=28178">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28178/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28178">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-28178.s20">
        <title>References</title>
        <ref id="article-28178.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agarwal</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Logie</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Morris</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Bradley</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Rotondo</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Bradfield</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Indelicato</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Esophagitis associated with multimodality management of pediatric Ewing sarcoma of thorax.</article-title>
            <source>Pediatr Blood Cancer</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>65</volume>
            <issue>6</issue>
            <fpage>e27006</fpage>
            <pub-id pub-id-type="pmid">29431250</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28178.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Verma</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Simone</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Werner-Wasik</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Acute and Late Toxicities of Concurrent Chemoradiotherapy for Locally-Advanced Non-Small Cell Lung Cancer.</article-title>
            <source>Cancers (Basel)</source>
            <year>2017</year>
            <month>Sep</month>
            <day>08</day>
            <volume>9</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">28885561</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28178.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simone</surname>
                <given-names>CB</given-names>
              </name>
            </person-group>
            <article-title>Thoracic Radiation Normal Tissue Injury.</article-title>
            <source>Semin Radiat Oncol</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>27</volume>
            <issue>4</issue>
            <fpage>370</fpage>
            <page-range>370-377</page-range>
            <pub-id pub-id-type="pmid">28865520</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28178.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>So</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Radiotherapy in anaplastic thyroid carcinoma: An Australian experience.</article-title>
            <source>J Med Imaging Radiat Oncol</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>61</volume>
            <issue>2</issue>
            <fpage>279</fpage>
            <page-range>279-287</page-range>
            <pub-id pub-id-type="pmid">28387011</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28178.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baker</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fairchild</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Radiation-induced esophagitis in lung cancer.</article-title>
            <source>Lung Cancer (Auckl)</source>
            <year>2016</year>
            <volume>7</volume>
            <fpage>119</fpage>
            <page-range>119-127</page-range>
            <pub-id pub-id-type="pmid">28210168</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28178.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gong</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jiang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Predictors for severe acute esophagitis in lung cancer patients treated with chemoradiotherapy: a systematic review.</article-title>
            <source>Curr Med Res Opin</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>32</volume>
            <issue>10</issue>
            <fpage>1701</fpage>
            <page-range>1701-1708</page-range>
            <pub-id pub-id-type="pmid">27341659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28178.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murro</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jakate</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Radiation esophagitis.</article-title>
            <source>Arch Pathol Lab Med</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>139</volume>
            <issue>6</issue>
            <fpage>827</fpage>
            <page-range>827-30</page-range>
            <pub-id pub-id-type="pmid">26030254</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28178.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ma</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xia</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>An esophagus-sparing technique to limit radiation esophagitis in locally advanced non-small cell lung cancer treated by simultaneous integrated boost intensity-modulated radiotherapy and concurrent chemotherapy.</article-title>
            <source>Radiat Oncol</source>
            <year>2018</year>
            <month>Jul</month>
            <day>17</day>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>130</fpage>
            <pub-id pub-id-type="pmid">30016978</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28178.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yau</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Lindsay</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Le</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Glick</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bezjak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>BCJ</given-names>
              </name>
              <name>
                <surname>Hope</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Giuliani</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Low Incidence of Esophageal Toxicity After Lung Stereotactic Body Radiation Therapy: Are Current Esophageal Dose Constraints Too Conservative?</article-title>
            <source>Int J Radiat Oncol Biol Phys</source>
            <year>2018</year>
            <month>Jul</month>
            <day>01</day>
            <volume>101</volume>
            <issue>3</issue>
            <fpage>574</fpage>
            <page-range>574-580</page-range>
            <pub-id pub-id-type="pmid">29680259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28178.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ravich</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Endoscopic Management of Benign Esophageal Strictures.</article-title>
            <source>Curr Gastroenterol Rep</source>
            <year>2017</year>
            <month>Aug</month>
            <day>24</day>
            <volume>19</volume>
            <issue>10</issue>
            <fpage>50</fpage>
            <pub-id pub-id-type="pmid">28840483</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28178.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>IJ</given-names>
              </name>
            </person-group>
            <article-title>Predictors of post-treatment stenosis in cervical esophageal cancer undergoing high-dose radiotherapy.</article-title>
            <source>World J Gastroenterol</source>
            <year>2018</year>
            <month>Feb</month>
            <day>21</day>
            <volume>24</volume>
            <issue>7</issue>
            <fpage>862</fpage>
            <page-range>862-869</page-range>
            <pub-id pub-id-type="pmid">29467556</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28178.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yuce Sari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yazici</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Yuce</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Karabulut</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Cengiz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ozyigit</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The effect of glutamine and arginine-enriched nutritional support on quality of life in head and neck cancer patients treated with IMRT.</article-title>
            <source>Clin Nutr ESPEN</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>16</volume>
            <fpage>30</fpage>
            <page-range>30-35</page-range>
            <pub-id pub-id-type="pmid">28531452</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28178.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Challand</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Thureau</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Dubray</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Giraud</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>[Esophageal toxicity of radiation therapy: clinical risk factors and management].</article-title>
            <source>Cancer Radiother</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>5-6</issue>
            <fpage>364</fpage>
            <page-range>364-71</page-range>
            <pub-id pub-id-type="pmid">22925486</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28178.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Billiet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Peeters</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>De Ruysscher</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Focus on treatment complications and optimal management: radiation oncology.</article-title>
            <source>Transl Lung Cancer Res</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>187</fpage>
            <page-range>187-91</page-range>
            <pub-id pub-id-type="pmid">25806299</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
